about
Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes[Ileus of uncommon cause--important and weighty facts].Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.Common polymorphisms within the NR4A3 locus, encoding the orphan nuclear receptor Nor-1, are associated with enhanced beta-cell function in non-diabetic subjects.Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor AgonistsImplications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelinesInfluence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.The evolving place of incretin-based therapies in type 2 diabetesThe development of the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25). Part II: normative data from 1784 healthy people.Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives.Gastric inhibitory polypeptide: the neglected incretin revisited.Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions.The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue.Iodine-induced thyrotoxicosis after ingestion of kelp-containing tea.Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humansEmerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetesSitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion.Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
P50
Q28257069-2E6CD6F2-3ECC-4044-83BB-5E8B4DDAC7E0Q30383608-D131AE3C-AE3B-4255-84B7-C4D0BC978DDBQ31140641-143AF40F-CE94-4056-B24F-0AB42513D403Q33493597-97609DED-F10B-49F0-82C7-E377C7E84377Q33521451-83E1642D-E369-4985-BEF5-8008F97704B6Q33610842-FB854246-490F-492D-B671-8DE13E3EA72BQ33866576-A3A0B801-5DDE-44AD-B5A6-232C53E9E35BQ33866808-2B261FEE-C8A9-4EB2-9B86-70D5DCBBE1FFQ34069860-3F0EE4FB-A1AB-4726-A946-F43D67E57BF9Q34635520-977F0480-CD70-4F91-8182-E33BCA628E50Q34758871-2F67E1EB-74D0-47D1-BD27-3906F91A5959Q35086817-B641D585-67CD-4B3C-AC13-6A01C28F0E68Q35688754-161FE22E-362B-450F-BDB0-8983394D343EQ35760275-9BB3805B-9A4A-44F0-9492-E2C509C87659Q35901427-6F613CA5-2188-4C4B-83A9-D0C848CE6EF1Q36327020-0EBDA3AF-F10C-4929-AED5-D07ACA2D933CQ36516919-320EBD7F-56F1-435C-A8EC-DEF383AD5A1DQ36520758-88330D2C-8F9B-483E-9AF5-6B9E00C487ACQ36742067-92673F64-C1F4-4D8C-9B90-46E4024C3F8AQ36854023-3952D21B-CBD6-4F6A-BACA-5018C036BD05Q36883337-5F9DE457-E9C2-4F88-AC7B-18A495D82EFDQ37050280-91089261-9A12-44F4-84C0-9C9278C344C4Q37236329-A52531B9-E028-401A-AF2F-7568499577B2Q37339891-90FF71EA-D9C7-47DB-9764-5DCC6A897AFB
P50
description
onderzoeker
@nl
name
Baptist Gallwitz
@ast
Baptist Gallwitz
@en
Baptist Gallwitz
@es
Baptist Gallwitz
@nl
Baptist Gallwitz
@sl
type
label
Baptist Gallwitz
@ast
Baptist Gallwitz
@en
Baptist Gallwitz
@es
Baptist Gallwitz
@nl
Baptist Gallwitz
@sl
prefLabel
Baptist Gallwitz
@ast
Baptist Gallwitz
@en
Baptist Gallwitz
@es
Baptist Gallwitz
@nl
Baptist Gallwitz
@sl
P106
P21
P31
P569
2000-01-01T00:00:00Z